Article info
PDFResearch ethics
Paper
Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- Correspondence to Dr Arthur L Caplan, Division of Medical Ethics, NYU School of Medicine, New York City, NY 10016, USA ; Arthur.Caplan{at}nyumc.org
Citation
Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
Publication history
- Received March 15, 2018
- Revised June 6, 2018
- Accepted June 16, 2018
- First published July 7, 2018.
Online issue publication
October 25, 2018
Article Versions
- Previous version (7 July 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
- Expanded access: growing importance to public health
- Trump signs bill to give patients right to try drugs
- Emerging immunotherapies in multiple myeloma
- Plasma cell leukaemia with t(11;14) not responsive to venetoclax
- Shortage of essential antimicrobials: a major challenge to global health security
- First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
- Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of ‘compassionate therapies’ in times of catastrophic pandemics
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program